Trial Profile
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Glioma; Neuroblastoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 25 Aug 2021 Results of a population pharmacokinetic and exposure-safety analyses of alisertib in children enrolled in two clinical trials (NCT02444884 and NCT01154816) published in the Journal of Clinical Pharmacology
- 20 May 2015 New trial record